The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

Hepatology

Volumn 66, Issue 5, 2017, Pages 1444-1453

  Papatheodoridis, George V ^a   Idilman, Ramazan ^b   Dalekos, George N ^c   Buti, Maria ^d   Chi, Heng ^e   van Boemmel, Florian ^f   Calleja, Jose Luis ^g   Sypsa, Vana ^a   Goulis, John ^h   Manolakopoulos, Spilios ^a   Loglio, Alessandro ⁱ   Siakavellas, Spyros ^a   Keskın, Onur ^b   Gatselis, Nikolaos ^c   Hansen, Bettina E ^e   Lehretz, Maria ^f   de la Revilla, Juan ^g   Savvidou, Savvoula ^h   Kourikou, Anastasia ^a   Vlachogiannakos, Ioannis ^a   Galanis, Kostantinos ^c   Yurdaydin, Cihan ^b   Berg, Thomas ^f   Colombo, Massimo ^j   Esteban, Rafael ^d   Janssen, Harry L A ^e,k   Lampertico, Pietro ⁱ   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF THESSALY   (Greece)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; CHRONIC HEPATITIS B; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; EUROPE; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; TENOFOVIR;

EID: 85032647862     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29320     Document Type: Article

References (29)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008;8:167-178.
3. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-283.
4. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-356.
5. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-1116.
6. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-967.
7. Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013;19:8822-8830.
8. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
9. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933-944.
10. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363-370.
11. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
12. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-88.
13. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-1665.
14. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-574.
15. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-806.
16. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000;284:876-878.
17. Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015;121:3631-3638.
18. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013;58:427-433.
19. Chen YC, Peng C, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015;42:1182-1191.
20. Su TH, Hu TH, Chen CY, Huang Y, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755-1764.
21. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016;64:S84-S101.
22. Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection—EASL special conference. J Hepatol 2015;63:1238-1253.
23. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
24. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
25. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. J Hepatol 2003;38:1356-1358.
26. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
27. Cardoso AC, Carvalho-Filho RJ, Marcellin P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut 2011;60:759-764.
28. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010;375:1419-1420.
29. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-659.